Cue Biopharma stock jumped 41.6% as positive Phase 2 data for its urticaria treatment CUE-221 met key clinical endpoints, signaling a potential path toward regulatory advancement.
Positive Phase 2 topline results for CUE-221 met primary and key secondary endpoints, driving a 41.6% premarket share price surge.
Cue Biopharma shares rallied 41.6% in premarket trading following successful Phase 2 topline results for CUE-221, an anti-IgE monoclonal antibody targeting chronic spontaneous urticaria. The study met primary and secondary endpoints in patients inadequately controlled by antihistamines, positioning the drug for potential advancement into Phase 2b/3 trials.
CUE-221 is an investigational anti-IgE monoclonal antibody developed to treat moderate to severe chronic spontaneous urticaria, a condition characterized by recurring hives.
Cue Biopharma shares surged 41.6% in premarket trading, pushing the stock price above its previous 52-week high.